Other therapies

Keiji Iwatsuki, Naohito Hatta, Nagwa M. Elwan, Selma Ugurel, Lauren L. Lockwood, Jürgen C. Becker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prognostic factors for Langerhans cell histiocytosis (LCH) or class I histiocytosis may include: (1) the number of organs involved, (2) the severity of organ failure, and (3) the age of the patients. Complications such as hemophagocytic syndrome and thrombocytopenia also affect the prognosis [1-4]. In general, younger patients with widely disseminated disease and organ dysfunction have a high risk of mortality. In a series of 101 children with LCH [2], the overall survival rate was 79% at 1 year, 74% at 3 years, and 71% at 5 years; however, in patients with liver or spleen involvement, 1-year survival was 33% and 5-year survival was only 25%. In adult LCH [3], the probability of survival 5 years post diagnosis was 92.3% overall: 100% for patients with single-system disease, 87.8% for isolated pulmonary disease, and 91.7% for multisystem disease.

Original languageEnglish
Title of host publicationSkin Cancer - A World-Wide Perspective
PublisherSpringer Berlin Heidelberg
Pages355-369
Number of pages15
ISBN (Print)9783642050718
DOIs
Publication statusPublished - 2011

Fingerprint

Langerhans Cell Histiocytosis
Survival
Histiocytosis
Hemophagocytic Lymphohistiocytosis
Therapeutics
Thrombocytopenia
Lung Diseases
Spleen
Survival Rate
Mortality
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Iwatsuki, K., Hatta, N., Elwan, N. M., Ugurel, S., Lockwood, L. L., & Becker, J. C. (2011). Other therapies. In Skin Cancer - A World-Wide Perspective (pp. 355-369). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-05072-5_25

Other therapies. / Iwatsuki, Keiji; Hatta, Naohito; Elwan, Nagwa M.; Ugurel, Selma; Lockwood, Lauren L.; Becker, Jürgen C.

Skin Cancer - A World-Wide Perspective. Springer Berlin Heidelberg, 2011. p. 355-369.

Research output: Chapter in Book/Report/Conference proceedingChapter

Iwatsuki, K, Hatta, N, Elwan, NM, Ugurel, S, Lockwood, LL & Becker, JC 2011, Other therapies. in Skin Cancer - A World-Wide Perspective. Springer Berlin Heidelberg, pp. 355-369. https://doi.org/10.1007/978-3-642-05072-5_25
Iwatsuki K, Hatta N, Elwan NM, Ugurel S, Lockwood LL, Becker JC. Other therapies. In Skin Cancer - A World-Wide Perspective. Springer Berlin Heidelberg. 2011. p. 355-369 https://doi.org/10.1007/978-3-642-05072-5_25
Iwatsuki, Keiji ; Hatta, Naohito ; Elwan, Nagwa M. ; Ugurel, Selma ; Lockwood, Lauren L. ; Becker, Jürgen C. / Other therapies. Skin Cancer - A World-Wide Perspective. Springer Berlin Heidelberg, 2011. pp. 355-369
@inbook{dc3471d00d57416296db7f6da8ad3dcf,
title = "Other therapies",
abstract = "Prognostic factors for Langerhans cell histiocytosis (LCH) or class I histiocytosis may include: (1) the number of organs involved, (2) the severity of organ failure, and (3) the age of the patients. Complications such as hemophagocytic syndrome and thrombocytopenia also affect the prognosis [1-4]. In general, younger patients with widely disseminated disease and organ dysfunction have a high risk of mortality. In a series of 101 children with LCH [2], the overall survival rate was 79{\%} at 1 year, 74{\%} at 3 years, and 71{\%} at 5 years; however, in patients with liver or spleen involvement, 1-year survival was 33{\%} and 5-year survival was only 25{\%}. In adult LCH [3], the probability of survival 5 years post diagnosis was 92.3{\%} overall: 100{\%} for patients with single-system disease, 87.8{\%} for isolated pulmonary disease, and 91.7{\%} for multisystem disease.",
author = "Keiji Iwatsuki and Naohito Hatta and Elwan, {Nagwa M.} and Selma Ugurel and Lockwood, {Lauren L.} and Becker, {J{\"u}rgen C.}",
year = "2011",
doi = "10.1007/978-3-642-05072-5_25",
language = "English",
isbn = "9783642050718",
pages = "355--369",
booktitle = "Skin Cancer - A World-Wide Perspective",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Other therapies

AU - Iwatsuki, Keiji

AU - Hatta, Naohito

AU - Elwan, Nagwa M.

AU - Ugurel, Selma

AU - Lockwood, Lauren L.

AU - Becker, Jürgen C.

PY - 2011

Y1 - 2011

N2 - Prognostic factors for Langerhans cell histiocytosis (LCH) or class I histiocytosis may include: (1) the number of organs involved, (2) the severity of organ failure, and (3) the age of the patients. Complications such as hemophagocytic syndrome and thrombocytopenia also affect the prognosis [1-4]. In general, younger patients with widely disseminated disease and organ dysfunction have a high risk of mortality. In a series of 101 children with LCH [2], the overall survival rate was 79% at 1 year, 74% at 3 years, and 71% at 5 years; however, in patients with liver or spleen involvement, 1-year survival was 33% and 5-year survival was only 25%. In adult LCH [3], the probability of survival 5 years post diagnosis was 92.3% overall: 100% for patients with single-system disease, 87.8% for isolated pulmonary disease, and 91.7% for multisystem disease.

AB - Prognostic factors for Langerhans cell histiocytosis (LCH) or class I histiocytosis may include: (1) the number of organs involved, (2) the severity of organ failure, and (3) the age of the patients. Complications such as hemophagocytic syndrome and thrombocytopenia also affect the prognosis [1-4]. In general, younger patients with widely disseminated disease and organ dysfunction have a high risk of mortality. In a series of 101 children with LCH [2], the overall survival rate was 79% at 1 year, 74% at 3 years, and 71% at 5 years; however, in patients with liver or spleen involvement, 1-year survival was 33% and 5-year survival was only 25%. In adult LCH [3], the probability of survival 5 years post diagnosis was 92.3% overall: 100% for patients with single-system disease, 87.8% for isolated pulmonary disease, and 91.7% for multisystem disease.

UR - http://www.scopus.com/inward/record.url?scp=84891472143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891472143&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-05072-5_25

DO - 10.1007/978-3-642-05072-5_25

M3 - Chapter

AN - SCOPUS:84891472143

SN - 9783642050718

SP - 355

EP - 369

BT - Skin Cancer - A World-Wide Perspective

PB - Springer Berlin Heidelberg

ER -